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Abstract 
Mendelian traits associated with qualitative or quantitative abnormalities of mtDNA are presumably caused by mutations in 
nucleus-encoded genes that deleteriously interact with the mitochondrial genome. Qualitative abnormalities of mtDNA are typically 
represented by pleioplasmic multiple mtDNA deletions, that are detected in stable tissues, including skeletal muscle, of patients affected 
by Autosomal Dominant Chronic Progressive External Ophthalmoplegia. Quantitative abnormalities are represented by tissue-specific 
depletion of mtDNA, associated with different clinical presentations in infancy or childhood. Linkage analysis and search for candidate 
genes are two complementary strategies aimed at identifying the genes responsible for these disorders. 
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1. Introduction 
Mutations of human mitochondrial DNA (mtDNA) can 
be divided in: (i) single sporadic deletions or insertion-du- 
plications of mtDNA; (ii) maternally-inherited point muta- 
tions of mtDNA; and (iii) mutations of mtDNA inherited 
as mendelian traits (see Refs. [1-4] for recent reviews). 
The latter category of disorders indicates the existence 
of transmissible mutations in nuclear genes that can ulti- 
mately damage the structural integrity of the mtDNA 
molecule or the mtDNA copy number. 
Accordingly, two groups of mendelian mtDNA defects 
have been identified: qualitative alterations, i.e., multiple 
large-scale deletions of mtDNA, and quantitative decrease 
of the mtDNA copy number, i.e., tissue-specific depletion 
of mtDNA. 
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2. Qualitative abnormalities: multiple familial mtDNA 
deletions 
2.1. Autosomal Dominant Chronic Progressive External 
Ophthalmoplegia 
Multiple large-scale rearrangements of the mitochon- 
drial chromosome have been identified in the muscle 
biopsies of individuals affected by Autosomal Dominant 
Chronic Progressive External Ophthalmoplegia (AD- 
CPEO) [5-9]. Cardinal manifestations were adult-onset 
CPEO and a proximal mitochondrial myopathy, docu- 
mented by the presence of ragged-red fibres and partial 
cytochrome c oxidase deficiency in the muscle biopsy of 
the probands (Fig. 1). Biochemically, the activities of both 
respiratory complexes I and IV in muscle homogenates 
were usually decreased to about 50%. Additional frequent 
features included sensorineural hearing loss, vestibular are- 
flexia, and a cerebellar syndrome. Bilateral cataract, chronic 
sensorimotor peripheral neuropathy, extrapyramidal signs 
or affective disorders were occasionally present. Serum 
lactate at rest was normal or moderately elevated. 
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The penetrance of the disease is apparently very high: 
in our series, approx. 50% of isogenerational adult individ- 
uals were affected. However, some individuals appeared 
normal at the clinical examination, but had morphological 
and biochemical features indicating a sub-clinical mito- 
chondrial encephalomyopathy. 
From a molecular standpoint, Southern-blot analysis of 
muscle mtDNA from symptomatic and pre-symptomatic 
patients typically showed the presence of heterogeneous 
mtDNA species (so called 'pleioplasmy' of mtDNA), cor- 
responding to deleted mtDNAs co-existing with a variable 
amount of wild-type mtDNA. The latter was the only 
mtDNA species detectable in normal relatives (Fig. 1). 
Interestingly, the sub-clinically affected individuals had 
lesser amounts of pleioplasmic, deleted mtDNA 
(mtDNA a+) in their muscle biopsies, compared to clini- 
cally affected patients, indicating a quantitative relation 
between mtDNA damage and phenotypic expression. 
Moreover, the sub-clinically affected individuals were usu- 
ally younger than the symptomatic patients, suggesting an 
age-related accumulation of the mtDNA lesions in muscle. 
The molecular characterization of the rearranged 
mtDNA species [6] by both Southern-blot and PCR-based 
analyses has established the following points: (1) the major 
mtDNA region spanning from the origin of H-strand repli- 
cation (O H) to the origin of L-strand replication (O L) is 
preferentially affected by deletions, while the D-loop is 
conserved in all of the mutant species; (2) the molecular 
rearrangements occur across flanking direct repeats of 
variable length; (3) deletions are more abundant in post- 
mitotic tissues characterized by high dependency on aero- 
bic energy production such as muscle, heart and brain [9]. 
By contrast, deleted mtDNAs are virtually absent in tissues 
composed of rapid-turnover cells, indicating the existence 
of negative selection against he organelles that contain 
abnormal mtDNA species. Incidentally, the lack of a 
molecular phenotype in cells such as lymphocytes, fibrob- 
lasts or myoblasts has so far prevented from studying the 
pathogenesis of multiple mtDNA deletions in culture sys- 
tems. 
2.2. Clinical heterogeneity: other phenotypes 
As in many other mitochondrial disorders, phenotypic 
heterogeneity has occasionally been reported in association 
with multiple mtDNA deletions, although the AD-CPEO 
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Fig. 1. Clinical, molecular and morphological features of AD-CPEO mtDNA a +. Panel A. Bilateral ptosis and divergent strabismus in a typical AD-CPEO 
patient. Panel B. Southern-blot analysis of PvulI-digested muscle mtDNA. Lanes 2 and 3: samples from two brothers affected by AD-CPEO; lane 1: 
sample from a normal relative. Panel C: histochemical reaction for succinate dehydrogenase in a muscle biopsy from an AD-CPEO patient. The white 
asterisks indicate two ragged-red fibres. Panel D: histochemical reaction for cytochrome c oxidase on a serial section of the same muscle biopsy. Notice 
the absence of reaction in the two ragged-red fibres (black asterisks). 
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phenotype described above is by far the most frequent 
clinical presentation. Other phenotypes include autosomal 
recessive juvenile CPEO [10], incomplete Kearns-Sayre 
syndrome with metabolic attacks [11], familial recurrent 
myoglobinuria [12], familial cardiomyopathy [13], several 
cases of Mitochondrial Neuro-Gastro-Intestinal En- 
cephalopathy (MNGIE) [14], and a few patients affected 
by Inclusion-Body Myositis (IBM) [15]. The peculiar clini- 
cal features of these syndromes suggest that they should be 
considered as separate clinical entities. Indeed, the rele- 
vance of multiple mtDNA deletions in the pathogenesis of
some of these syndromes, uch as IBM, is unclear. 
2.3. AD-CPEO mt°NA a +: pathogenetic considerations 
A causative role of the observed mtDNA a+ pleio- 
plasmy in AD-CPEO mtDNA'-a+ is indicated by the strict 
correlation between the presence of the molecular lesions 
and the disease, and by the frequent association of single 
sporadic deletions with the CPEO phenotype [1-4]. 
Based on the pedigree analysis of our families, the 
mitochondrial genomes of affected individuals must be 
damaged by a dominant mutation in an unknown nuclear 
gene. It is possible that the abnormal product of this gene 
acts by facilitating and amplifying an intrinsic propensity 
of mtDNA to undergo rearrangements. For instance, direct 
repeats and palindromic sequences have been implicated as 
promoters of excision and recombination of long stretches 
of mtDNA in lower eukaryotes [16,17], in poikilotherm 
metazoans [18-20], and in human mitochondrial en- 
cephalomyopathies as ociated with single, apparently spo- 
radic mtDNA deletions [21]. In addition, mtDNA a+ have 
been detected in very low amounts in tissues of normal 
individuals over 40-50 years [22], and sequence hetero- 
geneity may occur in mtDNA of humans [23] and rodents 
[24] as an age-related phenomenon. 
Similar to single sporadic mtDNA deletions, multiple 
familiar deletions occur across flanking direct repeats, but 
in familial cases the repeats are frequently non-perfect, 
often very short (triplets or quadruplets) and sometimes 
slipped. Furthermore, deletions take place at hot-spot re- 
gions which were never been described in single, sporadic 
deletions [21]. Therefore, while the molecular mechanism 
of familiar D-mtDNA pleioplasmy is probably similar to 
that causing single 'spontaneous' deletions, both the fre- 
quency of and the propensity for deletional events are 
extremely potentiated in the familial cases. Alternatively, 
the mutation could affect a hypothetical factor devoted to 
select and eliminate abnormal mtDNAs. The latter possi- 
bility is supported by the observation that, with the excep- 
tions mentioned above, in normal mammalian tissues 
mtDNA heterogeneity is rare and usually confined to small 
length variations in the D-loop region [25], suggesting that 
extensive intra-individual mtDNA heterogeneity may not 
be tolerated and that heteroplasmic genomes are rapidly 
sorted-out [26,27]. 
2.4. Linkage analysis 
To identify the disease locus (or loci) for AD- 
CPEO mtDNA'~+ we have been collecting several Italian 
families that fulfil the following criteria: typical clinical 
features (see above); unequivocally demonstrated autoso- 
mal dominant pattern of inheritance; presence in the tested 
affected members of multiple mtDNA deletions in muscle; 
absence of the lesions in non-affected family members. 
To date, approx. 200 regularly spatiated microsatellite 
markers have been used to exclude more than 70% of the 
autosomal genome. Given the small size of the chromo- 
some pool available for the initial primary linkage analy- 
sis, significant results for each marker could be obtained 
only by pooling together the lod scores calculated in each 
family. This procedure is based on the arbitrary assump- 
tion that the trait is homogeneous in the tested families. 
However, genetic heterogeneity cannot be excluded. In- 
deed, both our exclusion data, and a comparison with 
results of linkage analysis performed on a large Finnish 
family by Suomalainen and co-workers, strongly indicate 
that the disease is in fact heterogeneous and that more than 
one locus is associated with AD-CPEO mtDNAA+, possibly 
on the basis of geographic or ethnic segregation. More- 
over, incomplete penetrance, or variability of the age of 
onset could further complicate the interpretation of the 
results. 
Recently, two of our families have been substantially 
expanded by collecting new individuals. Each of these two 
families is now large enough to provide significant iod 
scores with fully informative markers, and a second link- 
age screening is currently underway to identify the locus 
specific for each family. 
3. Quantitative abnormalities: depletion of mtDNA 
In 1991, Moraes et al. [28] reported severe depletion of 
mtDNA in seven infants affected from birth by different 
organ-specific syndromes, uch as myopathy, hepatopathy 
or nephropathy, all characterized by faulty oxidative phos- 
phorylation (OXPHOS) metabolism in the affected tissues. 
In addition to the severe form, characterized by early 
onset, rapidly progressive fatal course and mtDNA deple- 
tion to up to 98% in affected tissues, Tritschler et al. [29] 
described a milder phenotype in three patients, in whom a 
slowly progressive mitochondrial encephalomyopathy 
starting in childhood was associated with less severe de- 
crease in the amount of mtDNA in skeletal muscle, rang- 
ing from 14% to 34%. 
3.1. mtDNA depletion: pathogenetic considerations 
It is likely that mtDNA depletion is a genetically het- 
erogenous condition. For instance, the report of apparently 
sporadic cases, or of families in which maternal inheri- 
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tance cannot be excluded raise the possibility that in some 
cases a cis-mutation of mtDNA, affecting regions involved 
in replication, may produce the molecular phenotype. 
However, no mutations in crucial regions such as the 
D-loop or the origin of replication of the mtDNA light 
strands have been so far observed in association with 
mtDNA depletion. 
On the contrary, the involvement of siblings of both 
sexes, born from healthy parents, suggests that in most 
cases mtDNA depletion is transmitted as an autosomal 
recessive trait, possibly affecting a nuclear DNA gene 
controlling the mtDNA copy number. Evidence in support 
of the nuclear origin of the responsible gene has been 
recently provided by Bodnar et al. [30] in one case in 
which depletion could be corrected by transferring 'de- 
pleted' mitochondria from fibroblasts of an affected indi- 
vidual in mtDNA-less human tumoral cells containing a 
nuclear gene set different from that of the donor. 
One possibility [28] is that the fundamental genetic 
defect, presumably nuclear-encoded, causes an error in the 
resumption of mitochondrial division and mtDNA replica- 
tion in early embryogenesis. After fertilization, the number 
of mitochondria nd mtDNAs in the zygote does not 
change appreciably until the blastocyst stage. If the timing 
of resumption were delayed until the time of germ-layer 
differentiation, the individual stem cell populations could 
contain abnormally reduced numbers of mtDNAs, which 
could produce a permanent tissue-specific depletion of 
mtDNA during embryonal, fetal and post-natal develop- 
ment. 
However, we have shown that in mtDNA depletion 
associated with infantile myopathy, the molecular pheno- 
type is confined to muscle, while other cell types, includ- 
ing fibroblasts, lymphocytes, myoblasts and myotubes have 
normal amounts of mtDNA and are biochemically normal 
[31]. It is known that cultured myoblasts derive from 
muscle satellite cells, i.e., cells which retain the myogenic 
potential, but become metabolically and mitotically dor- 
mant at the earliest stages of embryonic muscle differentia- 
tion. Therefore, the observation that both myoblasts and 
myotubes of patients had normal levels of mtDNA sug- 
gests that expression of the defective gene causing mtDNA 
depletion occur during a stage of muscle differentiation 
later than the formation of myotubes, possibly after inner- 
vation of the muscle fibres. The availability of methods 
which allow the neuralization of muscle fibres in cell 
culture systems will help test this hypothesis. 
4. Candidate genes 
Nuclear genes specifying factors involved in the replica- 
tion of the human mitochondrial genome can be consid- 
ered as candidates for disorders associated to nucleus- 
driven mutations of mtDNA. 
Our knowledge on the set of nuclear gene products 
implicated in mtDNA replication is still incomplete. Al- 
though a number of protein products involved in mtDNA 
transcription/replication hasbeen identified and partially 
purified in vertebrates, the cDNAs encoding for only three 
proteins involved in mtDNA housekeeping functions have 
been cloned and characterized in humans or mammals. 
These cDNAs specify the mitochondrial Transcription Fac- 
tor A (mtTFA), the mitochondrial Single-Stranded DNA 
Binding Protein (mtSSB) and a new mitochondrial endonu- 
clease, Endonuclease G.
MtTFA is the main activator of transcription of both the 
heavy and the light strand. Moreover, since mtDNA repli- 
cation relies upon synthesis of RNA primers binding to the 
origin of replication of the heavy strand, mtTFA is essen- 
tial for mtDNA replication as well. The mtTFA cDNA and 
gene have been cloned in humans by Parisi and co-workers 
[32]. 
MtSSB is a single stranded mtDNA binding protein that 
acts as a homotetramer thoroughly coating the displaced 
H-strand uring replication [33,34]. In doing so, the mtSSB 
is supposed to prevent he formation of secondary struc- 
tures and illegitimate pairings between the single DNA 
strands during replication. According to the currently ac- 
cepted models for the generation of mtDNA deletions, the 
formation of mtDNA secondary structures, as well as the 
exposure of 'naked' tracts of single stranded mtDNA are 
essential in promoting the illegitimate association between 
direct repeats which may ultimately lead to deletions. 
Finally, endonuclease G is a recently discovered mito- 
chondrial enzyme, that preferentially cleaves GC-rich 
DNA, as well as RNA, tracts [35]. The physiological role 
of endonuclease G is still unclear. The most likely possibil- 
ities are that the enzyme may contribute to the maturation 
of the RNA primers in the initial phase of mtDNA replica- 
tion, or to the generation of mature mtDNA-specific tran- 
scripts. 
In principle, deleterious mutations in each of these three 
genes could produce lesions of mtDNA leading to disease. 
For instance, defective mtTFA is expected to determine 
either qualitative or quantitative abnormalities of mito- 
chondrial transcription, and, possibly, replication [36]. 
Yeast abf2 null mutants are lacking the ABF2 gene, also 
called HIM1 [37,38], the putative analog of mtTFA. Abf2- 
mutant cannot grow in media containing a nonfermentable 
carbon source as glycerol, due to either loss of mtDNA or 
impaired mtDNA expression. A reduction of mtTFA 
cross-reacting material has indeed been reported in associ- 
ation with tissue-specific depletion of mtDNA [39]. How- 
ever, it is still unclear whether the decline of mtTFA is 
primary or secondary to mtDNA depletion. On the other 
hand, mutations of E. coli single-stranded DNA binding 
protein (SSB), the prokaryotic analog of mtSSB, produce a
lethal phenotype due to impairment of DNA replication 
[40]. Likewise, a pO phenotype associated with mutations 
of RIM1 [41], the yeast analog of human mtSSB, has 
recently been described in S. cereuisiae. In addition to 
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absence of mtDNA replication, mutations of mtSSB could 
also produce alterations in the fidelity of mtDNA replica- 
tion, and promote the accumulat ion of errors in the mtDNA 
sequence and/or  rearrangements of the molecule. Finally, 
if the proposed role of endoG in the mtDNA replication- 
initiation, or mtRNA processing, will be confirmed, h-en- 
doG mutations hould also affect either mtDNA propaga- 
tion, or gene expression, or both. 
We recently identified and cloned the cDNAs corre- 
sponding to Xenopus laevis [42], rat and human mtSSB 
genes [43]. The mature proteins are highly conserved with 
each other and three regions of the protein are similar to 
corresponding domains of the SSB of E. coli, indicating 
the existence of a broad class of DNA-binding proteins 
with structural and functional similarities both in prokary- 
otes and in prokaryote-derived organelles. We are cur- 
rently carrying out the characterization of the mtSSB gene 
organization, including the analysis of the promotor re- 
gion, as well as the in vivo effects of different mtSSB 
mutations. The long-term aim of this work is to obtain 
models of mitochondrial disorders both in culture systems 
and in transgenic animals. 
Moreover, taking advantage from the available full- 
length bovine endoG cDNA, we have isolated a partial- 
length cDNA encoding approximately two-thirds of the 
carboxy-terminus of human endonuclease G [44]. 
Finally, by using both human-rodent somatic-cell hy- 
brids and FISH, we have localized the human mtTFA, 
mtSSB and EndoG genes on chromosomes 10, 7 and 9, 
respectively [44]. Sequence analysis of the corresponding 
cDNAs, retro-transcribed from affected individuals, as well 
as specific l inkage analysis of the chromosomal regions 
containing these genes, will verify their role in the etiology 
of AD-CPEO mtDNA a+ and mtDNA depletion. 
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